February 1, 2019 / 1:20 PM / 5 months ago

BRIEF-Roche - CHMP Recommends Eu Approval Of Tecentriq

Feb 1 (Reuters) - Roche Holding AG:

* CHMP RECOMMENDS EU APPROVAL OF ROCHE'S TECENTRIQ IN COMBINATION WITH AVASTIN AND CHEMOTHERAPY AS AN INITIAL TREATMENT FOR LUNG CANCER

* EUROPEAN MEDICINES AGENCY’S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) HAS RECOMMENDED THE APPROVAL OF TECENTRIQ® (ATEZOLIZUMAB), IN COMBINATION WITH AVASTIN, PACLITAXEL AND CARBOPLATIN, FOR THE FIRST-LINE TREATMENT OF ADULTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

* THE CHMP RECOMMENDATION IS BASED ON RESULTS FROM THE PHASE III IMPOWER150 STUDY Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below